Targeting tumor intrinsic TAK1 engages TNF-α-driven cell death through distinct mechanisms and enhances cancer...

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Immune checkpoint inhibitors (ICIs) show promise in cancer treatment, but many patients lack response or develop resistance.
• Novel strategies are needed to enhance the efficacy of existing immunotherapies.
• CRISPR screens identified TNF-α signaling mediators, like TAK1, as crucial for tumor cell susceptibility to cytotoxic T cells.

Purpose of the Study:

• To investigate the role of TAK1 in tumor cell sensitization to TNF-α-induced cytotoxicity.
• To explore the therapeutic potential of TAK1 inhibition in combination with immunotherapy.

Main Methods:

• Utilized CRISPR screens to identify key mediators in TNF-α signaling.
• Employed pharmacologic inhibition and genetic deletion of TAK1 in tumor cells.
• Assessed tumor cell apoptosis and in vivo tumor growth in preclinical cancer models.
• Evaluated the impact of TAK1 inhibition on α-PD-1 immunotherapy response and anti-tumor memory.

Main Results:

• Pharmacologic TAK1 inhibition sensitized tumor cells to TNF-α-induced RIPK1-dependent apoptosis.
• Genetic deletion of TAK1 induced RIPK1-independent apoptosis, suggesting a novel scaffolding role.
• Tak1 deletion impaired tumor growth, enhanced α-PD-1 immunotherapy, and established durable anti-tumor memory.
• These effects were dependent on CD8 T cells and intact TNF-α signaling.

Conclusions:

• Targeting TAK1 within tumor cells enhances TNF-α-mediated cytotoxicity.
• Compromising TAK1 function boosts anti-tumor immunity and generates durable responses in preclinical cancer models.
• TAK1 inhibition represents a promising strategy to augment existing cancer immunotherapies.